These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 21834094)

  • 1. Optimisation of the anti-Trypanosoma brucei activity of the opioid agonist U50488.
    Smith VC; Cleghorn LA; Woodland A; Spinks D; Hallyburton I; Collie IT; Mok NY; Norval S; Brenk R; Fairlamb AH; Frearson JA; Read KD; Gilbert IH; Wyatt PG
    ChemMedChem; 2011 Oct; 6(10):1832-40. PubMed ID: 21834094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a κ-opioid agonist as a potent and selective lead for drug development against human African trypanosomiasis.
    Jones DC; Hallyburton I; Stojanovski L; Read KD; Frearson JA; Fairlamb AH
    Biochem Pharmacol; 2010 Nov; 80(10):1478-86. PubMed ID: 20696141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Trypanosoma brucei leucyl-tRNA synthetase inhibitors by pharmacophore- and docking-based virtual screening and synthesis.
    Zhao Y; Wang Q; Meng Q; Ding D; Yang H; Gao G; Li D; Zhu W; Zhou H
    Bioorg Med Chem; 2012 Feb; 20(3):1240-50. PubMed ID: 22249121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of N-(2-aminoethyl)-N-benzyloxyphenyl benzamides: New potent Trypanosoma brucei inhibitors.
    Buchynskyy A; Gillespie JR; Hulverson MA; McQueen J; Creason SA; Ranade RM; Duster NA; Gelb MH; Buckner FS
    Bioorg Med Chem; 2017 Mar; 25(5):1571-1584. PubMed ID: 28187957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flavonoid-derived Privileged Scaffolds in anti-Trypanosoma brucei Drug Discovery.
    Boniface PK; Elizabeth FI
    Curr Drug Targets; 2019; 20(12):1295-1314. PubMed ID: 31215385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activity of Aromathecins against African Trypanosomes.
    Nenortas NP; Cinelli MA; Morrell AE; Cushman M; Shapiro TA
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of nucleoside hydrolase inhibitors for treatment of African trypanosomiasis.
    Berg M; Kohl L; Van der Veken P; Joossens J; Al-Salabi MI; Castagna V; Giannese F; Cos P; Versées W; Steyaert J; Grellier P; Haemers A; Degano M; Maes L; de Koning HP; Augustyns K
    Antimicrob Agents Chemother; 2010 May; 54(5):1900-8. PubMed ID: 20194690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of arylsubstituted imidazoles derivatives as antiprotozoal agents and docking studies on sterol 14α-demethylase (CYP51) from Trypanosoma cruzi, Leishmania infantum, and Trypanosoma brucei.
    Rojas Vargas JA; López AG; Pérez Y; Cos P; Froeyen M
    Parasitol Res; 2019 May; 118(5):1533-1548. PubMed ID: 30903349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-(Oxazolo[4,5-b]pyridin-2-yl)anilides as a novel class of potent inhibitors for the kinetoplastid Trypanosoma brucei, the causative agent for human African trypanosomiasis.
    Ferrins L; Rahmani R; Sykes ML; Jones AJ; Avery VM; Teston E; Almohaywi B; Yin J; Smith J; Hyland C; White KL; Ryan E; Campbell M; Charman SA; Kaiser M; Baell JB
    Eur J Med Chem; 2013 Aug; 66():450-65. PubMed ID: 23831695
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation and inhibition of CTP synthase from Trypanosoma brucei, the causative agent of African sleeping sickness.
    Steeves CH; Bearne SL
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5188-90. PubMed ID: 21840216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the HSP60/10 chaperonin systems of Trypanosoma brucei as a strategy for treating African sleeping sickness.
    Abdeen S; Salim N; Mammadova N; Summers CM; Goldsmith-Pestana K; McMahon-Pratt D; Schultz PG; Horwich AL; Chapman E; Johnson SM
    Bioorg Med Chem Lett; 2016 Nov; 26(21):5247-5253. PubMed ID: 27720295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of 2-(1H-imidazo-2-yl)piperazines as a new class of potent and non-cytotoxic inhibitors of Trypanosoma brucei growth in vitro.
    Ferrigno F; Biancofiore I; Malancona S; Ponzi S; Paonessa G; Graziani R; Bresciani A; Gennari N; Di Marco A; Kaiser M; Summa V; Harper S; Ontoria JM
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3689-3692. PubMed ID: 30482621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo anti-Trypanosoma brucei activities of phenazinomycin and related compounds.
    Otoguro K; Ishiyama A; Iwatsuki M; Namatame M; Nishihara-Tukashima A; Nakashima T; Shibahara S; Kondo S; Yamada H; Omura S
    J Antibiot (Tokyo); 2010 Sep; 63(9):579-81. PubMed ID: 20588299
    [No Abstract]   [Full Text] [Related]  

  • 14. Alterations in the stereochemistry of the kappa-selective opioid agonist U50,488 result in high-affinity sigma ligands.
    de Costa BR; Bowen WD; Hellewell SB; George C; Rothman RB; Reid AA; Walker JM; Jacobson AE; Rice KC
    J Med Chem; 1989 Aug; 32(8):1996-2002. PubMed ID: 2547074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Promising lead compounds for novel antiprotozoals.
    Otoguro K; Iwatsuki M; Ishiyama A; Namatame M; Nishihara-Tukashima A; Shibahara S; Kondo S; Yamada H; Omura S
    J Antibiot (Tokyo); 2010 Jul; 63(7):381-4. PubMed ID: 20661239
    [No Abstract]   [Full Text] [Related]  

  • 16. QSAR analysis for 6-arylpyrazine-2-carboxamides as Trypanosoma brucei inhibitors.
    Masand VH; El-Sayed NN; Mahajan DT; Rastija V
    SAR QSAR Environ Res; 2017 Feb; 28(2):165-177. PubMed ID: 28235390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probes for narcotic receptor mediated phenomena. 17. Synthesis and evaluation of a series of trans-3,4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)cyclohexyl]benzeneacet amide (U50,488) related isothiocyanate derivatives as opioid receptor affinity ligands.
    de Costa BR; Rothman RB; Bykov V; Band L; Pert A; Jacobson AE; Rice KC
    J Med Chem; 1990 Apr; 33(4):1171-6. PubMed ID: 2157008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the Trypanosoma brucei Hsp83 potential as a target for structure guided drug design.
    Pizarro JC; Hills T; Senisterra G; Wernimont AK; Mackenzie C; Norcross NR; Ferguson MA; Wyatt PG; Gilbert IH; Hui R
    PLoS Negl Trop Dis; 2013; 7(10):e2492. PubMed ID: 24147171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Profiling the anti-protozoal activity of anti-cancer HDAC inhibitors against Plasmodium and Trypanosoma parasites.
    Engel JA; Jones AJ; Avery VM; Sumanadasa SD; Ng SS; Fairlie DP; Skinner-Adams T; Andrews KT
    Int J Parasitol Drugs Drug Resist; 2015 Dec; 5(3):117-26. PubMed ID: 26199860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Squalamine analogues as potential anti-trypanosomal and anti-leishmanial compounds.
    Khabnadideh S; Tan CL; Croft SL; Kendrick H; Yardley V; Gilbert IH
    Bioorg Med Chem Lett; 2000 Jun; 10(11):1237-9. PubMed ID: 10866389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.